Business
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded inducement grants on February 2, 2026 to two new employees under Bicara’s 2026 Inducement Plan as a material inducement to employment. The employees received, in the aggregate, non-qualified stock options to purchase 158,900 shares of Bicara’s common stock
About this update from Bicara Therapeutics Inc.
[{"type":"image","alt":"Bicara Therapeutics Inc.","displaySize":"","headline":null,"caption":"Bicara Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":86,"url":"https://media.zenfs.com/en/globenewswire.com/6ccfcafb8abd88270fbc9bc7dafef0fe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/N7aaUVu45bXz.VUeCxgrhA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6ccfcafb8abd88270fbc9bc7dafef0fe","width":300,"height":86}},"lazy":false},{"type":"text","content":"BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded inducement grants on February 2, 2026 to two new employees under Bicara’s 2026 Inducement Plan as a material inducement to employment.","length":378,"tagName":"p"},{"type":"text","content":"The employees received, in the aggregate, non-qualified stock options to purchase 158,900 shares of Bicara’s common stock, par value $0.0001 per share, with an exercise price of $16.76 per share, equal to the closing price of Bicara’s common stock as reported by Nasdaq on February 2, 2026. One-fourth of the options vest on the first anniversary of the employee’s applicable start date, with the remaining options vesting in 12 equal quarterly installments thereafter, subject to the employee’s continued service with the company through each applicable vesting date.","length":568,"tagName":"p"},{"type":"text","content":"All of the above-described awards were granted outside of Bicara’s stockholder-approved equity incentive plans and are pursuant to Bicara’s 2026 Inducement Plan, which was adopted by Bicara’s board of directors in January 2026. The awards were approved by the compensation committee of Bicara’s board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with Bicara in accordance with Nasdaq Listing Rule 5635(c)(4).","length":496,"tagName":"p"},{"type":"text","content":"About Bicara TherapeuticsBicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara’s lead program, ficerafusp alfa, ...